Biotech Breakthrough: Cingulate Receives FDA Clearance for ADHD Treatment

Cingulate, a biotechnology company specializing in the development of drugs for underserved conditions, has achieved a significant milestone in its mission to enhance ADHD treatment. Dr. Ann Childress and Shane Schaffer, Chairman & CEO of Cingulate, recently appeared on Benzinga’s All Access to discuss the company’s groundbreaking advancements.

Cingulate has pioneered a revolutionary technology known as Precision Timed Release™ (PTR™). This proprietary technology enables a single pill to contain multiple doses of a drug, providing relief to individuals burdened by the need to take multiple pills for chronic conditions. The development of PTR™ has the potential to significantly improve the quality of life for patients with ADHD and other conditions.

In a major stride forward, Cingulate has received clearance from the U.S. Food and Drug Administration (FDA) to seek full approval for its lead candidate, CTx-1301. This clearance is a testament to the company’s dedication to innovation and its commitment to addressing the unmet needs of patients with ADHD.

CTx-1301 holds great promise as a potential game-changer in ADHD treatment. With the FDA’s clearance, Cingulate can now move forward with the necessary steps to bring this innovative drug to market. By streamlining medication administration through the use of PTR™ technology, CTx-1301 has the potential to alleviate the pill burden faced by individuals with ADHD, ultimately improving treatment adherence and patient outcomes.

Cingulate’s breakthrough in ADHD treatment has garnered attention from investors and industry experts alike. The company’s commitment to developing novel solutions for underserved conditions positions it as a leader in the biotechnology sector. With the FDA clearance in hand, Cingulate is poised to make a significant impact on the lives of individuals living with ADHD.

To learn more about Cingulate’s groundbreaking advancements and the potential of CTx-1301, watch the full interview with Dr. Ann Childress and Shane Schaffer on Benzinga’s All Access.

Contact:
{
“name”: “Johnny Rice”,
“email”: “info@benzinga.com”,
“phone”: “+1 877-440-9464”
}

More Posts

SWEP, a world-leading supplier of brazed plate heat exchangers (BPHEs), has unveiled its latest innovation …

Village Super Market, Inc. (NASDAQ: VLGEA) is deeply saddened to announce the passing of William …

Vicinity Motor Corp., a leading North American supplier of commercial electric vehicles, has announced the …